Progression-Free Survival: Meaningful or Simply Measurable?

被引：252

作者：

Booth, Christopher M. ^{[1
]}

Eisenhauer, Elizabeth A. ^{[1
]}

机构：

[1] Queens Univ, NCIC Clin Trials Grp, Kingston, ON, Canada

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 10期

关键词：

SURROGATE END-POINTS; RANDOMIZED CLINICAL-TRIALS; DISEASE PROGRESSION; OVARIAN-CANCER; TIME; VALIDATION; 1ST-LINE; PACLITAXEL; GEFITINIB; ONCOLOGY;

D O I：

10.1200/JCO.2011.38.7571

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1030 / 1033

页数：4

共 41 条

[1] Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs [J].

Amir, Eitan ;

Seruga, Bostjan ;

Martinez-Lopez, Joaquin ;

Kwong, Ryan ;

Pandiella, Atanasio ;

Tannock, Ian F. ;

Ocana, Alberto .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) :2543-2549

[2]

[Anonymous], BIOMARKERS CLIN DRUG

[3]

Basler MH, 2009, BRIT MED J, V339, P3141

[4] Clinical trial endpoints in ovarian cancer: Report of an FDA/ASCO/AACR public workshop [J].

Bast, Robert C. ;

Thigpen, J. Tate ;

Arbuck, Susan G. ;

Basen-Engquist, Karen ;

Burke, Laurie B. ;

Freedman, Ralph ;

Horning, Sandra J. ;

Ozols, Robert ;

Rustin, Gordon J. ;

Spriggs, David ;

Wenzel, Lari B. ;

Pazdur, Richard .

GYNECOLOGIC ONCOLOGY, 2007, 107 (02) :173-176

[5] On the use of surrogate end points in randomized trials [J].

Begg, CB ;

Leung, DHY .

JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-STATISTICS IN SOCIETY, 2000, 163 :15-24

[6] Evolution of the Randomized Controlled Trial in Oncology Over Three Decades [J].

Booth, Christopher M. ;

Cescon, David W. ;

Wang, Lisa ;

Tannock, Ian F. ;

Krzyzanowska, Monika K. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) :5458-5464

[7] Validation of surrogate end points in multiple randomized clinical trials with failure time end points [J].

Burzykowski, T ;

Molenberghs, G .

JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS, 2001, 50 :405-422

[8] Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer [J].

Burzykowski, Tomasz ;

Buyse, Marc ;

Piccart-Gebhart, Martine J. ;

Sledge, George ;

Carmichael, James ;

Lueck, Hans-Joachim ;

Mackey, John R. ;

Nabholtz, Jean-Marc ;

Paridaens, Robert ;

Biganzoli, Laura ;

Jassem, Jacek ;

Bontenbal, Marijke ;

Bonneterre, Jacques ;

Chan, Stephen ;

Basaran, Gul Atalay ;

Therasse, Patrick .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) :1987-1992

[9] Criteria for the validation of surrogate endpoints in randomized experiments [J].

Buyse, M ;

Molenberghs, G .

BIOMETRICS, 1998, 54 (03) :1014-1029

[10] Progression-free survival is a surrogate for survival in advanced colorectal cancer [J].

Buyse, Marc ;

Burzykowski, Tomasz ;

Carroll, Kevin ;

Michiels, Stefan ;

Sargent, Daniel J. ;

Miller, Langdon L. ;

Elfring, Gary L. ;

Pignon, Jean-Pierre ;

Piedbois, Pascal .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) :5218-5224

← 1 2 3 4 5 →